Kidney study for people with HIV and advanced kidney disease
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at how the HIV medicine tenofovir (TAF) is processed by the body in people with advanced kidney disease. It aims to help doctors understand the right dose for patients with kidney problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have chronic kidney disease (eGFR less than 45 for at least 3 months) and your current kidney function is below 30 (or between 30 and 44 with special approval)
- You are not on dialysis and have not been on dialysis in the past 90 days
- You have been taking a stable HIV medicine regimen that includes TAF and FTC for at least 3 months
- Your HIV is well controlled (all recent viral loads under 200 copies/mL) for more than 6 months
- You are not pregnant or breastfeeding (if female)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral HIV medication (VH4524184) in people who have never taken HIV treatment before. It looks at how well the drug controls the virus and how safe it is.
This study tests how taking two tablets of a PrEP medication (F/TAF) at once affects healthy volunteers. It helps us understand the safety and how the body processes the drug.
This study looks at whether taking tenofovir for hepatitis B for more than five years affects kidney function. If you have hepatitis B and have been on this medicine long-term, this trial will help understand if your kidneys need monitoring.
This trial tests different HIV medicines in children and teenagers to find safer, more effective options. It aims to improve viral suppression and overall health for young people living with HIV.
This study follows adults who are at high risk of getting HIV while they take HIV prevention pills (PrEP). It aims to learn how well PrEP fits real-life use in people at risk and who may need extra care.
This study tests a new long-acting HIV medication taken by mouth that may allow you to switch from your current daily pill. It is for people who have had an undetectable HIV viral load for at least 6 months and are currently on a stable HIV treatment.
Hear when a new Kidney Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.